Revolution Medicines has dosed the first subject in the Phase III RASolve 301 trial with daraxonrasib (RMC-6236) for NSCLC.

Today we're going to take a closer look at Mid-Cap Health Care company Revolution Medicines, whose shares are currently trading at $41.23. We've been asking ourselves whether the company is under or ...

QDoc leads the industry in showing how technological innovation can advance public health and environmental sustainability. In an age where reducing emissions is a global imperative, virtual health ...

The anti-mRNA sentiment — coupled with the sweeping shake-up of science funding across the United States — has sparked fears ...

Q1 2025 Management View CEO Mark Goldsmith highlighted significant advancements in the company's strategic priorities, particularly in the development of RAS(ON) inhibitors targeting RAS-addicted ...

New non-small cell lung cancer clinical data from RAS (ON) inhibitor portfolio support strategies for first-line metastatic and earlier lines of treatment REDWOOD CITY, Calif., May 07, 2025 (GLOBE ...

But, many of the biological medicines have gone off-patent. Now, India faces a new challenge: ensuring these biological ...

Patanjali, backed by a team of more than 500 scientists at its research institute, has validated the effectiveness of its ...

KRAS-targeted therapies, including daraxonrasib and zoldonrasib, show promise in overcoming resistance in cancer treatment, ...

AI grabs the headlines, but behind the scenes, automated dispensing systems and robotic fulfillment centers are already changing the way prescriptions are processed.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...